• India’s first CRISPR Covid-19 test, developed by the Tata Group and CSIR-IGIB, has been approved for use in India.
• The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from the Drug Controller General of India (DCGI) for commercial launch.
• This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus.
• CRISPR is a genome editing technology for diagnosing diseases. The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19.
• The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use.
• The Tata Group has worked closely with CSIR-IGIB and ICMR to create this high-quality test.
Mains Paper 3: Science and Tech
Prelims level: CRISPR test
Mains level: Key highlights about the CRISPR test